注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Cue Biopharma Inc是一家处于发展阶段的免疫治疗公司。该公司致力于开发用于选择性调节与疾病相关的T细胞亚群,以治疗癌症和自身免疫性疾病的生物制剂。其免疫肿瘤产品包括CUE-100框架和CUE-200框架;自身免疫性产品包括MHC I类项目和MHC II类项目。CUE-100框架限制了T细胞群的活性。CUE-200框架可实现有效的,长期的抗肿瘤T细胞反应。其自身免疫疾病疗法保护健康细胞免受免疫攻击。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Pamela Garzone | - | - | Director |
Steven C. Almo | 62 | 2015 | Co-Founder and Chairman of Scientific & Clinical Advisory Board |
Daniel R. Passeri | 62 | 2016 | CEO & Director |
Frank Morich | 70 | 2018 | Independent Chairman of the Board |
Hidde L. Ploegh | - | - | Member of Scientific & Clinical Advisory Board |
Abul K. Abbas | - | 2021 | Member of Scientific Advisory Board |
Michael Kalos | - | 2021 | Member of Scientific Advisory Board |
Kenneth J. Pienta | 63 | 2017 | Clinical Advisor |
David Baker | - | - | Member of Scientific & Clinical Advisory Board |
Rafi Ahmed | - | 2023 | Member of Scientific Advisory Board |
Pamela D. Garzone | 68 | 2023 | Independent Director |
Patrick Verheyen | 63 | 2023 | Independent Director |
Karolina Palucka | - | 2017 | Member of Scientific & Clinical Advisory Board |
Peter A. Kiener | 72 | 2016 | Independent Director |
Frederick W. Driscoll | 73 | 2018 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核